196808-45-4

Basic information

• Product Name: Farglitazar
• Synonyms: Farglitazar;2(S)-(2-Benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid;G1 262570;GI 262570;GI 262570X;N-(2-Benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
• CAS NO: 196808-45-4
• Molecular Formula: C₃₄H₃₀N₂O₅
• Molecular Weight: 546.6124
• Mol File: 196808-45-4.mol

Chemical Properties

• Boiling Point: 793.7°C at 760 mmHg
• Flash Point: 433.8°C
• Appearance: /
• Density: 1.257g/cm³
• Vapor Pressure: 1.45E-26mmHg at 25°C
• Refractive Index: 1.639
• CAS DataBase Reference: Farglitazar(CAS DataBase Reference)
• NIST Chemistry Reference: Farglitazar(196808-45-4)
• EPA Substance Registry System: Farglitazar(196808-45-4)

Safety Data

• Hazardous Substances Data: 196808-45-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Farglitazar is used as an insulin action enhancer for the treatment of type 2 diabetes. It helps to improve insulin sensitivity, allowing the body to better regulate blood sugar levels and manage the disease more effectively.
Used in Hepatic Fibrosis Treatment:
Farglitazar is used as a potential therapeutic agent for treating hepatic fibrosis, a chronic liver disease characterized by excessive scarring and tissue damage. As a PPAR agonist, it may help to reduce inflammation and promote tissue repair, potentially slowing the progression of the disease.

InChI:InChI=1/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1

Upstream product

• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 3580-38-9 2-Benzoylcyclohexanone 
• 219598-15-9 2(S)-<(2-benzoylphenyl)amino>-3-<4-<2-(5-methyl-2-phenyl-3H-imidazol-4-yl)ethoxy>phenyl>propionic acid methyl ester 
• 827-43-0 4-methyl-2-phenyl-1H-imidazole 
• 1026353-08-1 2-(2-benzoyl-phenylamino)-3-(4-{2-[5-methyl-2-phenyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4-yl]-ethoxy}-phenyl)-propionic acid methyl ester 
• 196810-09-0 (S)-2-<(2-benzoylphenyl)amino>-3-(4-hydroxyphenyl)propionic acid methyl ester 
• 1080-06-4 L-Tyr-OMe 
• 196810-20-5 (2S)-<(2-benzoylphenyl)amino>-3-<4-<2-(5-methyl-2-phenyloxazol4-yl)ethoxy>phenyl>propionic acid methyl ester 
• 196810-90-9 2-<3-<(trimethylsilylethoxy)methyl>-5-methyl-2-phenyl-3H-imidazol-4-yl>ethanol 

Downstream Products

• 550357-29-4 (S)-2-(2-Benzoyl-phenylamino)-N-((R)-1-formyl-2-methyl-propyl)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionamide 
• 550357-28-3 (S)-2-(2-Benzoyl-phenylamino)-N-((R)-1-hydroxymethyl-2-methyl-propyl)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionamide 

Relevant articles and documents

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula

N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

We have identified a novel series of antidiabetic N-(2-benzoylphenyl)- L-tyrosine derivatives which are potent, selective PPARγ agonists. Through the use of in vitro PPARγ binding and functional assays (2S)-3-(4- (benzyloxy)phenyl)-2-((1-methyl-3-oxo-3-ph

N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety

We previously reported the identification of (2S)-((2- benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-phenyloxazol-4- yl)ethoxy]phenyl}propanoic acid (2) (PPARγ pK(i) = 8.94, PPARγ pEC50 = 9.47) as a potent and selective PPARγ agonist. We now report the expanded structure-activity relationship around the phenyl alkyl ether moiety by pursuing both a classical medicinal chemistry approach and a solid-phase chemistry approach for analogue synthesis. The solution-phase strategy focused on evaluating the effects of oxazole and phenyl ring replacements of the 2-(5-methyl-2-phenyloxazol-4-yl)ethyl side chain of 2 with several replacements providing potent and selective PPARγ agonists with improved aqueous solubility. Specifically, replacement of the phenyl ring of the phenyloxazole moiety with a 4-pyridyl group to give 2(S)-((2- benzoylphenyl)amino)-3-{4-[2-(5-methyl-2-pyridin-4-yloxazol-4- yl)ethoxy]phenyl}propionic acid (16) (PPARγ pK(i) = 8.85, PPARγ pEC50 = 8.74) or a 4-methylpiperazine to give 2(S)-((2-benzoylphenyl)amino)-3-(4- {2-[5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl]ethoxy}phenyl)propionic acid (24) (PPARγ pK(i) = 8.66, PPARγ pEC50 = 8.89) provided two potent and selective PPARγ agonists with increased solubility in pH 7.4 phosphate buffer and simulated gastric fluid as compared to 2. The second strategy took advantage of the speed and ease of parallel solid-phase analogue synthesis to generate a more diverse set of phenyl alkyl ethers which led to the identification of a number of novel, high-affinity PPARγ ligands (PPARγ pK(i)'s 6.98-8.03). The combined structure-activity data derived from the two strategies provide valuable insight on the requirements for PPARγ binding, functional activity, selectivity, and aqueous solubility.